Literature DB >> 24999598

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Johan Staaf1, Katja Harbst1, Martin Lauss1, Markus Ringnér1, Anna Måsbäck2, Jillian Howlin1, Karin Jirström3, Mark Harland4, Abdlsattar Zebary5, Jane M Palmer6, Christian Ingvar7, Håkan Olsson1, Julia Newton-Bishop4, Johan Hansson5, Nicholas Hayward6, Nelleke Gruis7, Göran Jönsson8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24999598     DOI: 10.1038/jid.2014.272

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  15 in total

Review 1.  Genetics of melanoma predisposition.

Authors:  Nicholas K Hayward
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

2.  Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.

Authors:  Fabrice Jardin; Jean-Philippe Jais; Thierry-Jo Molina; Françoise Parmentier; Jean-Michel Picquenot; Philippe Ruminy; Hervé Tilly; Christian Bastard; Gilles-André Salles; Pierre Feugier; Catherine Thieblemont; Christian Gisselbrecht; Aurelien de Reynies; Bertrand Coiffier; Corinne Haioun; Karen Leroy
Journal:  Blood       Date:  2010-04-30       Impact factor: 22.113

Review 3.  Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.

Authors:  Richard A Scolyer; Georgina V Long; John F Thompson
Journal:  Mol Oncol       Date:  2011-03-21       Impact factor: 6.603

4.  Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

Authors:  Göran Jönsson; Christian Busch; Stian Knappskog; Jürgen Geisler; Hrvoje Miletic; Markus Ringnér; Johan R Lillehaug; Ake Borg; Per Eystein Lønning
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

5.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

6.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

Authors:  Abdlsattar Zebary; Katarina Omholt; Remco van Doorn; Paola Ghiorzo; Katja Harbst; Carolina Hertzman Johansson; Veronica Höiom; Göran Jönsson; Dace Pjanova; Susana Puig; Giovanna B Scarra; Mark Harland; Håkan Olsson; Suzanne Egyhazi Brage; Jane Palmer; Lena Kanter-Lewensohn; Ismini Vassilaki; Nicholas K Hayward; Julia Newton-Bishop; Nelleke A Gruis; Johan Hansson
Journal:  J Invest Dermatol       Date:  2013-06-14       Impact factor: 8.551

9.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Authors:  Satoru Yokoyama; Susan L Woods; Glen M Boyle; Lauren G Aoude; Stuart MacGregor; Victoria Zismann; Michael Gartside; Anne E Cust; Rizwan Haq; Mark Harland; John C Taylor; David L Duffy; Kelly Holohan; Ken Dutton-Regester; Jane M Palmer; Vanessa Bonazzi; Mitchell S Stark; Judith Symmons; Matthew H Law; Christopher Schmidt; Cathy Lanagan; Linda O'Connor; Elizabeth A Holland; Helen Schmid; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Mark A Jenkins; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; David C Whiteman; Paul D Pharoah; Douglas F Easton; Alison M Dunning; Julia A Newton-Bishop; Grant W Montgomery; Nicholas G Martin; Graham J Mann; D Timothy Bishop; Hensin Tsao; Jeffrey M Trent; David E Fisher; Nicholas K Hayward; Kevin M Brown
Journal:  Nature       Date:  2011-11-13       Impact factor: 49.962

10.  POT1 loss-of-function variants predispose to familial melanoma.

Authors:  Carla Daniela Robles-Espinoza; Mark Harland; Andrew J Ramsay; Lauren G Aoude; Víctor Quesada; Zhihao Ding; Karen A Pooley; Antonia L Pritchard; Jessamy C Tiffen; Mia Petljak; Jane M Palmer; Judith Symmons; Peter Johansson; Mitchell S Stark; Michael G Gartside; Helen Snowden; Grant W Montgomery; Nicholas G Martin; Jimmy Z Liu; Jiyeon Choi; Matthew Makowski; Kevin M Brown; Alison M Dunning; Thomas M Keane; Carlos López-Otín; Nelleke A Gruis; Nicholas K Hayward; D Timothy Bishop; Julia A Newton-Bishop; David J Adams
Journal:  Nat Genet       Date:  2014-03-30       Impact factor: 38.330

View more
  3 in total

1.  Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.

Authors:  William Bruno; Claudia Martinuzzi; Bruna Dalmasso; Virginia Andreotti; Lorenza Pastorino; Francesco Cabiddu; Marina Gualco; Francesco Spagnolo; Alberto Ballestrero; Paola Queirolo; Federica Grillo; Luca Mastracci; Paola Ghiorzo
Journal:  Oncotarget       Date:  2017-12-14

2.  Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation.

Authors:  Marine Melixetian; Daniela Bossi; Marija Mihailovich; Simona Punzi; Iros Barozzi; Federica Marocchi; Alessandro Cuomo; Tiziana Bonaldi; Giuseppe Testa; Jean-Christophe Marine; Eleonora Leucci; Saverio Minucci; Pier Giuseppe Pelicci; Luisa Lanfrancone
Journal:  EMBO Rep       Date:  2021-02-15       Impact factor: 8.807

3.  Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants.

Authors:  Francesco Spagnolo; Bruna Dalmasso; Enrica Tanda; Miriam Potrony; Susana Puig; Remco van Doorn; Ellen Kapiteijn; Paola Queirolo; Hildur Helgadottir; Paola Ghiorzo
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.